Novo Nordisk's new Wegovy weight-loss pill records over 3,000 prescriptions in its first four days, signaling strong market entry as competition with Eli Lilly intensifies in the booming obesity treatment sector.
Strive Specialties files lawsuit against Eli Lilly and Novo Nordisk, alleging drugmakers blocked access to cheaper compounded versions of popular weight-loss medications through exclusive telehealth deals.
Novo Nordisk CEO says company is open to acquisitions of any size to strengthen its obesity drug portfolio following competition from Eli Lilly and loss of Metsera to Pfizer.
Amazon Pharmacy now sells Wegovy weight-loss pill. Insured pay $25/month, uninsured start at $149. Needle-free option available nationwide.
Eli Lilly acquires Ventyx Biosciences for $1.2 billion to advance oral therapies targeting chronic inflammation in heart, brain, and autoimmune diseases.
Novo Nordisk's once-daily Wegovy pill launches in the U.S. at $149/month for self-paying customers, intensifying competition with Eli Lilly in the weight-loss drug market.
